The Alopecia Areata market growth is driven by factors like increase in the prevalence of Alopecia Areata, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Alopecia Areata market report also offers comprehensive insights into the Alopecia Areata market size, share, Alopecia Areata epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Alopecia Areata market size growth forward.
Some of the key highlights from the Alopecia Areata Market Insights Report:
- Several key pharmaceutical companies, including Concert Pharmaceuticals, Pfizer, Legacy Healthcare, and others, are developing novel products to improve the Alopecia Areata treatment outlook.
- The total Alopecia Areata market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
- As per DelveInsight analysis, the Alopecia Areata market is anticipated to witness growth at a considerable CAGR
- In 2022, the US had a market size of ~USD 110 million. The market size is expected to undergo a significant shift by 2032.
- In 2022, topical steroids generated the largest revenue, i.e., ~USD 60 million in 2022, among all the other therapies in the US.
- Systemic steroids accounted for the second largest revenue share in the US, which was ~USD 22 million in 2022.
- OLUMIANT had the smallest market share, ~USD 2 million, in the US in 2022.
Strategise your business goals by understanding market dynamics @ Alopecia Areata Market Landscape
Alopecia Areata Overview
According to the National Alopecia areata Foundation (NAAF), Alopecia areata is a common autoimmune skin disease, causing hair loss on the scalp, face, and sometimes on other areas of the body, affecting people of all ages, both sexes, and all ethnic groups can develop Alopecia areata. There are different types of Alopecia areata, among which the three main forms include: Alopecia areata patchy, Alopecia totalis, and Alopecia universalis. Persistent patchy Alopecia areata, diffuse Alopecia areata, and ophiasis Alopecia are Alopecia areata’s other observed clinical variants. It is one of many recognized forms of Alopecia; Alopecia areata is the second most common form after androgenetic Alopecia. It often first appears during childhood and can be different for everyone who has it. Visible symptoms include small, coin-sized, round patches of baldness on the scalp, although hair elsewhere, such as the beard, eyebrows, eyelashes, body, and limbs, can be affected. In some people, larger areas are affected, and occasionally it can involve the whole scalp (Alopecia totalis) or even the entire body and scalp (Alopecia universalis).
Alopecia areata is known as a “polygenic disease” due to its genetic predisposition; about 20% of people with Alopecia areata have a family history. In Alopecia areata, hair loss is mainly due to inflammation caused by an attack of hair follicles by the body’s immune system, but the exact cause behind this autoimmune disorder is still unknown.
Do you know the treatment paradigms for different countries? Download our Alopecia Areata Market Sample Report
Alopecia Areata Epidemiology Insights
- In 2022, the total prevalent cases of Alopecia areata in the US were ~704,000 cases, which are anticipated to increase by 2032.
- The diagnosed cases of Alopecia areata were ~435,000 in the US in 2022.
- As per type-specific cases of Alopecia areata, the Alopecia areata (patchy) type accounted for ~437,000 cases, whereas beard Alopecia areata accounted for the least number of cases, i.e., ~3,500 cases in the US in 2022.
- In 2022, the cases as per the age of onset were ~592,000 cases before 40 years, whereas, after 40 years, there were ~113,000 cases in the US.
Alopecia Areata Epidemiology Segmentation
DelveInsight’s Alopecia Areata market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Alopecia Areata historical patient pools and forecasted Alopecia Areata patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Alopecia Areata Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Alopecia Areata Prevalence
- Age-Specific Alopecia Areata Prevalence
- Gender-Specific Alopecia Areata Prevalence
- Diagnosed and Treatable Cases of Alopecia Areata
Visit for more @ Alopecia Areata Epidemiological Insights
Recent Advancements in the Alopecia Areata Market
Ahmad Amin, MD: Effects of the FDA Approval of Ritlecitinib for Adolescents with Alopecia Areata- During this HCPLive interview, Ahmad Amin, MD, spoke about his own views on the recent US Food and Drug Administration (FDA) approval of once-per-day ritlecitinib for alopecia areata in adolescent patients.
Alopecia Areata Treatment Market
Alopecia areata is a common autoimmune skin disease that causes hair loss on the scalp, face, and sometimes on other body areas. Alopecia areata treatment involves corticosteroids, topical sensitization therapy, topical irritation therapy, and others. Topical corticosteroids possess fewer side effects and are widely used as a first-line treatment for Alopecia areata; available in different formulations, shampoos, and foams, it is generally well-tolerated with patient compliance for Alopecia areata treatment. Intralesional injection of corticosteroids alone or combined with topical corticosteroids is also recommended for patchy Alopecia areata. The preferable corticosteroid is triamcinolone acetonide. Usually, 3–5 sessions are performed every 4–6 weeks. Systemic corticosteroids are used in the treatment of Alopecia areata as oral pulse therapy (PT), intravenous (IV) PT, intramuscularly (IM), or continuously (CT).
Topical sensitization with DPCP is recommended for long-lasting (>2 years) extensive Alopecia areata, Alopecia totalis, and universalis, with its use being off-label. In this modality, the sensitizer DPCP is applied to induce allergic contact dermatitis that enables hair regrowth through an unknown mechanism of action. Anthralin is an alternative to DPCP in extensive Alopecia areata or AT, especially in children, because of its fewer side effects, but it may also be performed in adults. The topical application of anthralin causes irritant dermatitis that promotes hair regrowth through an unknown mechanism of action.
Alopecia Areata Emerging Therapy Assessment
CTP-543 (deuruxolitinib): Concert Pharmaceuticals
CTP-543 (deuruxolitinib), an oral inhibitor of JAK1 and JAK2, is an investigational JAK inhibitor designed to target the immunological basis of Alopecia areata. The US FDA has granted BTD and Fast Track Designation (FTD) to CTP-543 for treating Alopecia areata. Recently, the company has presented the positive results from two Phase III studies (THRIVE-AA1, THRIVE-AA2) at the 31st European Academy of Dermatology and Venereology (EADV) Congress. Furthermore, the company intends to submit the NDA and the data from the THRIVE-AA1 study to the US FDA in the first half of 2023.
PF-06651600 (ritlecitinib): Pfizer
PF-06651600 (ritlecitinib), a dual inhibitor of the TEC family of tyrosine kinases and JAK3 is an investigational oral once-daily treatment, i.e., the first in a new class of oral highly selective kinase inhibitors. The US FDA has granted BTD to PF-06651600 for treating Alopecia areata. The company recently announced positive results from two Phase III studies (ALLEGRO-IIb/III, ALLEGRO-LT). Furthermore, the US FDA and EMA have accepted the New Drug Application (NDA) and Marketing Authorization Application (MAA) for ritlecitinib in Alopecia areata.
Alopecia Areata Key Companies
- Concert Pharmaceuticals
- Pfizer
- Legacy Healthcare
For more information, visit Alopecia Areata Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Alopecia Areata Market Report:
- 10 Years Forecast
- 7MM Coverage
- Descriptive overview of Alopecia Areata, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Alopecia Areata epidemiology in the 7MM
- Alopecia Areata marketed and emerging therapies
- Alopecia Areata companies
- Alopecia Areata market drivers and barriers
Key Questions Answered in the Alopecia Areata Market Report 2032:
- What was the Alopecia Areata market share distribution in 2019, and how would it appear in 2032?
- What is the total Alopecia Areata market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Alopecia Areata market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Alopecia Areata market projected to expand at 7MM?
Table of Contents:
1 Alopecia Areata Market Key Comprehensive Insights
2 Alopecia Areata Market Report Introduction
3 Competitive Intelligence Analysis for Alopecia Areata
4 Alopecia Areata Market Analysis Overview at a Glance
5 Executive Summary of Alopecia Areata
6 Alopecia Areata Epidemiology and Market Methodology
7 Alopecia Areata Epidemiology and Patient Population
8 Alopecia Areata Patient Journey
9 Alopecia Areata Treatment Algorithm, Alopecia Areata Current Treatment, and Medical Practices
10 Key Endpoints in Alopecia Areata Clinical Trials
11 Alopecia Areata Marketed Therapies
12 Alopecia Areata Emerging Therapies
13 Alopecia Areata: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Alopecia Areata
16 Alopecia Areata Market Key Opinion Leaders Reviews
18 Alopecia Areata Market Drivers
19 Alopecia Areata Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Alopecia Areata Epidemiology 2032
DelveInsight’s “Alopecia Areata – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Alopecia Areata epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Alopecia Areata Pipeline 2023
“Alopecia Areata Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Alopecia Areata market. A detailed picture of the Alopecia Areata pipeline landscape is provided, which includes the disease overview and Alopecia Areata treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/